Indeed, PPIs can induce secondary hypergastrinemia, which in certain PPI-treated individuals can lead to significantly elevated plasma gastrin levels and a heightened risk of high-grade dysplasia or CRC [22]. The gene discussed is GAST; the disease is colorectal carcinoma.